OBX insider transaction filings
Obsidian Therapeutics, Inc. — 6 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-05. Screen OBX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 6 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Barrett Peter — Director | 1 | — | — | 1 |
| Fardis Maria — Director | 1 | — | — | 1 |
| Hagen Heidi — Director | 1 | — | — | 1 |
| Jagasia Madan — Chief Executive Officer, Director | 1 | — | — | 1 |
| Norkunas Matthew — Director | 1 | — | — | 1 |
| ROSS ROBERT W. — Director | 1 | — | — | 1 |
Recent Form 4 filings — Obsidian Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-05 | 4 | Barrett Peter — Director | Grant/award (A): 37,653 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Jagasia Madan — Chief Executive Officer, Director | Grant/award (A): 37,653 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Norkunas Matthew — Director | Grant/award (A): 37,653 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | ROSS ROBERT W. — Director | Grant/award (A): 37,653 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Fardis Maria — Director | Grant/award (A): 37,653 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Hagen Heidi — Director | Grant/award (A): 37,653 (derivative) @ $0 | EDGAR |
Recent 8-K events — Obsidian Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.02 — Results of Operations and Financial Condition 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 4.01 — Changes in Registrant's Certifying Accountant 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=OBX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →